118 related articles for article (PubMed ID: 37828756)
21. Complete Metabolic Response on Interim
Chen S; Ibrahim NK; Yan Y; Wong ST; Wang H; Wong FC
Oncologist; 2017 May; 22(5):526-534. PubMed ID: 28377466
[TBL] [Abstract][Full Text] [Related]
22. Verteporfin induces lipid peroxidation and ferroptosis in pancreatic cancer cells.
Zhou W; Lim A; Elmadbouh OHM; Edderkaoui M; Osipov A; Mathison AJ; Urrutia R; Liu T; Wang Q; Pandol SJ
Free Radic Biol Med; 2024 Feb; 212():493-504. PubMed ID: 38184120
[TBL] [Abstract][Full Text] [Related]
23. Verteporfin inhibits YAP-induced bladder cancer cell growth and invasion via Hippo signaling pathway.
Dong L; Lin F; Wu W; Liu Y; Huang W
Int J Med Sci; 2018; 15(6):645-652. PubMed ID: 29725256
[TBL] [Abstract][Full Text] [Related]
24. New insight on the correlation of metabolic status on
Wang Y; Zhao N; Wu Z; Pan N; Shen X; Liu T; Wei F; You J; Xu W; Ren X
Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1127-1136. PubMed ID: 31502013
[TBL] [Abstract][Full Text] [Related]
25. High mobility group protein B1 controls liver cancer initiation through yes-associated protein -dependent aerobic glycolysis.
Chen R; Zhu S; Fan XG; Wang H; Lotze MT; Zeh HJ; Billiar TR; Kang R; Tang D
Hepatology; 2018 May; 67(5):1823-1841. PubMed ID: 29149457
[TBL] [Abstract][Full Text] [Related]
26. The maximum standardized uptake value of metastatic site in 18 F-FDG PET/CT predicts molecular subtypes and survival in metastatic breast cancer: An Izmir Oncology Group study.
Cokmert S; Tanriverdi O; Karapolat I; Demir L; Bayoglu V; Can A; Akyol M; Yilmaz Y; Oktay Tarhan M
J BUON; 2016; 21(6):1410-1418. PubMed ID: 28039701
[TBL] [Abstract][Full Text] [Related]
27. Cancer-associated fibroblasts enhance tumor
Shangguan C; Gan G; Zhang J; Wu J; Miao Y; Zhang M; Li B; Mi J
Theranostics; 2018; 8(5):1376-1388. PubMed ID: 29507627
[No Abstract] [Full Text] [Related]
28. Prognostic value of maximum standard uptake value, metabolic tumor volume, and total lesion glycolysis of positron emission tomography/computed tomography in patients with breast cancer: A systematic review and meta-analysis.
Wen W; Xuan D; Hu Y; Li X; Liu L; Xu D
PLoS One; 2019; 14(12):e0225959. PubMed ID: 31826010
[TBL] [Abstract][Full Text] [Related]
29. "Verteporfin exhibits anti-proliferative activity in embryonal and alveolar rhabdomyosarcoma cell lines".
Sanna L; Piredda R; Marchesi I; Bordoni V; Forcales SV; Calvisi DF; Bagella L
Chem Biol Interact; 2019 Oct; 312():108813. PubMed ID: 31494105
[TBL] [Abstract][Full Text] [Related]
30. Increased Prostate Cancer Glucose Metabolism Detected by
Lavallée E; Bergeron M; Buteau FA; Blouin AC; Duchesnay N; Dujardin T; Tiguert R; Lacombe L; Fradet V; Makao-Nguile M; Fradet Y; Beauregard JM; Pouliot F
Eur Urol Focus; 2019 Nov; 5(6):998-1006. PubMed ID: 29609897
[TBL] [Abstract][Full Text] [Related]
31. Subtype-Guided
Wu S; Wang Y; Li J; Zhang N; Mo M; Klimberg S; Kaklamani V; Cochet A; Shao Z; Cheng J; Liu G
Oncologist; 2020 Apr; 25(4):e626-e633. PubMed ID: 32297448
[TBL] [Abstract][Full Text] [Related]
32. Comparison of
Mori M; Fujioka T; Ichikawa R; Inomata R; Katsuta L; Yashima Y; Yamaga E; Tsuchiya J; Hayashi K; Kumaki Y; Oda G; Nakagawa T; Onishi I; Kubota K; Tateishi U
Tomography; 2022 Oct; 8(5):2533-2546. PubMed ID: 36287810
[TBL] [Abstract][Full Text] [Related]
33. Verteporfin, a suppressor of YAP-TEAD complex, presents promising antitumor properties on ovarian cancer.
Feng J; Gou J; Jia J; Yi T; Cui T; Li Z
Onco Targets Ther; 2016; 9():5371-81. PubMed ID: 27621651
[TBL] [Abstract][Full Text] [Related]
34. Regulation of Hippo-YAP signaling by insulin-like growth factor-1 receptor in the tumorigenesis of diffuse large B-cell lymphoma.
Zhou X; Chen N; Xu H; Zhou X; Wang J; Fang X; Zhang Y; Li Y; Yang J; Wang X
J Hematol Oncol; 2020 Jun; 13(1):77. PubMed ID: 32546241
[TBL] [Abstract][Full Text] [Related]
35. Synthetic molecules targeting yes associated protein activity as chemotherapeutics against cancer.
Iftikhar R; Zahoor AF; Irfan M; Rasul A; Rao F
Chem Biol Drug Des; 2021 Dec; 98(6):1025-1037. PubMed ID: 34587361
[TBL] [Abstract][Full Text] [Related]
36.
Mitchell KG; Amini B; Wang Y; Carter BW; Godoy MCB; Parra ER; Behrens C; Villalobos P; Reuben A; Lee JJ; Weissferdt A; Moran CA; Fujimoto J; Sepesi B; Walsh GL; Vaporciyan AA; Hofstetter WL; William WN; Gibbons DL; Wang J; Hwu P; Swisher SG; Piwnica-Worms D; Kadara H; Wistuba II; Heymach JV; Peng W; Cascone T
Cancer Immunol Immunother; 2020 Aug; 69(8):1519-1534. PubMed ID: 32300858
[TBL] [Abstract][Full Text] [Related]
37. The clinically used photosensitizer Verteporfin (VP) inhibits YAP-TEAD and human retinoblastoma cell growth in vitro without light activation.
Brodowska K; Al-Moujahed A; Marmalidou A; Meyer Zu Horste M; Cichy J; Miller JW; Gragoudas E; Vavvas DG
Exp Eye Res; 2014 Jul; 124():67-73. PubMed ID: 24837142
[TBL] [Abstract][Full Text] [Related]
38. FSH Regulates YAP-TEAD Transcriptional Activity in Bovine Granulosa Cells to Allow the Future Dominant Follicle to Exert Its Augmented Estrogenic Capacity.
de Andrade LG; Portela VM; Dos Santos EC; Aires KV; Ferreira R; Missio D; da Silva Z; Koch J; Antoniazzi AQ; Gonçalves PBD; Zamberlam G
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430640
[TBL] [Abstract][Full Text] [Related]
39. Comparison of serum NEDD-9, CA 15-3, and CEA levels and PET metabolic parameters in breast cancer patients with 18 F-FDG PET / CT.
Arslan E; Aral H; Aksoy T; Afşar ÇU; Karabulut S; Trabulus FDC; Gürsu RU; Çermik TF
Rev Assoc Med Bras (1992); 2020 May; 66(5):673-679. PubMed ID: 32638964
[TBL] [Abstract][Full Text] [Related]
40. Verteporfin exhibits YAP-independent anti-proliferative and cytotoxic effects in endometrial cancer cells.
Dasari VR; Mazack V; Feng W; Nash J; Carey DJ; Gogoi R
Oncotarget; 2017 Apr; 8(17):28628-28640. PubMed ID: 28404908
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]